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Abstract
Background: Recently, we described a novel autoantibody, anti-Sj/ITPR1-IgG, that targets the inositol 1,4,5-trisphosphate
receptor type 1 (ITPR1) in patients with cerebellar ataxia. However, ITPR1 is expressed not only by Purkinje cells but also
in the anterior horn of the spinal cord, in the substantia gelatinosa and in the motor, sensory (including the dorsal root
ganglia) and autonomic peripheral nervous system, suggesting that the clinical spectrum associated with autoimmunity
to ITPR1 may be broader than initially thought. Here we report on serum autoantibodies to ITPR1 (up to 1:15,000) in
three patients with (radiculo)polyneuropathy, which in two cases was associated with cancer (ITPR1-expressing
adenocarcinoma of the lung, multiple myeloma), suggesting a paraneoplastic aetiology.
Methods: Serological and other immunological studies, and retrospective analysis of patient records.
Results: The clinical findings comprised motor, sensory (including severe pain) and autonomic symptoms. While one
patient presented with subacute symptoms mimicking Guillain-Barré syndrome (GBS), the symptoms progressed slowly in
two other patients. Electrophysiology revealed delayed F waves; a decrease in motor and sensory action potentials and
conduction velocities; delayed motor latencies; signs of denervation, indicating sensorimotor radiculopolyneuropathy of
the mixed type; and no conduction blocks. ITPR1-IgG belonged to the complement-activating IgG1 subclass in the
severely affected patient but exclusively to the IgG2 subclass in the two more mildly affected patients. Cerebrospinal
fluid ITPR1-IgG was found to be of predominantly extrathecal origin. A 3H-thymidine-based proliferation assay
confirmed the presence of ITPR1-reactive lymphocytes among peripheral blood mononuclear cells (PBMCs).
Immunophenotypic profiling of PBMCs protein demonstrated predominant proliferation of B cells, CD4 T cells and CD8
memory T cells following stimulation with purified ITPR1 protein. Patient ITPR1-IgG bound both to peripheral nervous
tissue and to lung tumour tissue. A nerve biopsy showed lymphocyte infiltration (including cytotoxic CD8 cells),
oedema, marked axonal loss and myelin-positive macrophages, indicating florid inflammation. ITPR1-IgG serum titres
declined following tumour removal, paralleled by clinical stabilization.
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Conclusions: Our findings expand the spectrum of clinical syndromes associated with ITPR1-IgG and suggest that
autoimmunity to ITPR1 may underlie peripheral nervous system diseases (including GBS) in some patients and may be
of paraneoplastic origin in a subset of cases.
Keywords: Anti-neuronal autoantibodies, Inositol 1,4,5-trisphosphate type 1 receptor antibodies, Paraneoplastic
neurological syndrome, Guillain-Barré syndrome (GBS), Acute sensorimotor polyradiculopathy, Polyneuropathy, Neuritis,
Autonomic neuropathy, Lung cancer, Adenocarcinoma of the lung, Multiple myeloma, Pain, Cranial nerve palsy, Facial
nerve paralysis, Autoimmune cerebellar ataxia, Neuropathology
Background
Recently, we described a new autoantibody (Ab) reactiv-
ity in patients with autoimmune cerebellar ataxia (ACA)
which targets the inositol 1,4,5-trisphosphate receptor
type 1 (ITPR1; also termed IP3RI) [1]. In the adult brain,
ITPR1 is strongly expressed in Purkinje cells (PC) of the
cerebellum, in hippocampal neurons (particularly in
CA1 pyramidal cells) [2–4], and in the cerebral cortex
(most pronounced in pyramidal layer V and in non-
pyramidal layer II) [2, 3].
However, expression of ITPR1 has been found also in
neuronal and glial cells (probably oligodendrocytes) in
the posterior and anterior horn of the spinal cord [2, 3]
and in neurons in the sensory dorsal root ganglia (DRG),
the trigeminal ganglia and the sympathetic ganglia [2].
Moreover, ITPR1 has been implicated in nociception,
with dysregulation of ITPR1 inhibition in the DRG lead-
ing to allodynia and hyperalgesia in mice [5]; ITPR1 is
also expressed at a high level in the nociceptive substan-
tia gelatinosa [3]. Here we report on three anti-ITPR1-
positive patients who developed symptoms compatible
with damage to the second motor neuron and/or first
sensory neuron, with additional involvement of the auto-
nomic nervous system and severe neurogenic pain in
one of them. Of particular note, ITPR1 autoimmunity
was associated with lung cancer in one of our patients
and with multiple myeloma in another, suggesting a
paraneoplastic aetiology.
In addition, we immunologically characterized the
ITPR1-Ab-related immune response by investigating (i.)
the peripheral blood mononuclear cell (PBMC) pheno-
typic profile associated with ITPR1-IgG positivity and
the phenotype alterations in the PBMC compartment
following stimulation with ITPR1, (ii.) the origin of
ITPR1-IgG in the cerebrospinal fluid (CSF), and (iii.) the
ITPR1 immunoglobulin (Ig) class and subclass dis-
tribution. Furthermore, we studied the expression
profiles of ITPR1 in the spinal cord, DRG and sural
nerve. Finally, we provide evidence in favour of a
paraneoplastic aetiology of ITPR1 autoimmunity by
demonstrating both expression of ITPR1 by the pa-
tient’s lung tumour and binding of patient IgG to the
tumour tissue.
Methods
Immunohistochemistry
Testing for ITPR1-IgG, ITPR1-IgM and ITPR1-IgA by im-
munohistochemistry (IHC) was performed as previously
described [1]. Briefly, 4-μm cryosections of mouse, rat and
primate cerebellum and primate spinal cord (Euroimmun,
Lübeck, Germany) and 10-μm cryosections of rat DRG tis-
sue (Zyagen, San Diego, CA) as well as cryosections from
an adenocarcinoma of the lung removed from a ITPR1-
IgG-positive patient (patient 1) were carefully thawed and
subsequently treated with formalin for 3 min, CHAPS for
3 min and 10 % goat serum for 1 h. Sections were then
incubated for 1 h with diluted patient and control serum
and with CSF samples. Binding of patient serum and CSF
IgG was visualized using a goat secondary antibody to
human IgG labelled with Alexa Fluor® (AF) 488 and a goat
secondary antibody to human IgG labelled with FITC
(Euroimmun), respectively. Binding of a commercial rabbit
anti-ITPR1 antibody (Dianova, Hamburg, Germany) was
detected using a goat anti-rabbit IgG AF568 antibody
(Invitrogen, Karlsruhe, Germany). The rabbit anti-ITPR1
antibody was chosen because it recognizes an epitope that,
according to UniProt data, shares no sequence homology
with ITPR2 and ITPR3.
ITPR1-Ig class and subclass analysis
For further evaluation of Ig classes and IgG subclasses,
unconjugated sheep anti-human IgG antibodies specific
for IgG subclasses 1 to 4 (The Binding Site, Schwetzingen,
Germany) and fluorescein isothiocyanate (FITC)-labelled
goat antibodies specific for human IgA and IgM were
substituted for the FITC-labelled goat anti-human IgG
antibody and an Alexa Fluor® 568-labelled donkey anti-
sheep IgG secondary antibody (Invitrogen; absorbed
against human IgG) was used to detect the IgG subclass-
specific secondary antibodies.
ITPR1-specific dot-blot assay
The presence of ITPR1-specific IgG was confirmed using
an immunoblot assay employing purified native ITPR1
from rat brain as previously described [1]. Briefly,
Protran BA79 nitrocellulose membranes (Whatman)
were spotted with increasing dilutions of full-length
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ITPR1 purified from rat cerebellum [6] and of ARH-
GAP26 (Abnova) in 0.1 % bovine serum albumin (BSA).
After drying, membranes were blocked with 5 % BSA in
Tris-buffered saline (TBS) for 1 h at room temperature
(RT), washed three times in TBS with 0.05 % Tween
(TBS-T) and finally incubated with a 1:20 dilution of the
patient serum in 0.1 % BSA/TBS-T for 1 h at RT. A don-
key anti-human IgG antibody labelled with IRdye 700DX
(Rockland) was used to detect bound IgG. Stripes were fi-
nally washed in TBS and analysed using an Odyssey™
fluorescence scanner (Licor, Lincoln, NE, USA) and Odys-
sey™ 2.0.40 application software (Licor). As controls,
serum samples from healthy donors and ARHGAP26-
IgG-positive patients [7–9] were tested in the same run.
ITPR1-specific cell-based assay
Finally, specificity of the patients’ IgG response for ITPR1
was further confirmed using a cell-based assay (CBA) as
previously reported [1]. Briefly, murine full-length ITPR1
was expressed in human embryonic kidney (HEK) 293 cells.
HEK293 cells were then grown on sterile cover glasses for
48 h and subsequently fixed with acetone. Cover glasses
were then cut into millimetre-sized fragments (biochips),
which were used as assay substrate. Biochips with mock-
transfected HEK293 cells were used as control substrate.
Both substrates were incubated with the patients’ serum
samples or control samples in parallel. Bound IgG was
detected using a goat secondary antibody to human IgG
labelled with FITC (Euroimmun).
ITPR1-specific antibody index
A paired CSF/serum sample obtained 27 days after onset
of symptoms was available from patient 1. To assess the
origin of CSF ITPR1, the ITPR1-specific antibody index
(AI), AIITPR1, was calculated [10–12]. Briefly, AIITPR1
values were calculated as the ratio between the CSF/serum
quotient for ITPR1-IgG, QITPR1, and the CSF/serum
quotient for total IgG, QIgG, i.e. AIITPR1 =QITPR1/QIgG. If
ITPR1-IgG are produced intrathecally, QITPR1 would
exceed QIgG, resulting in AIITPR1 values >1. Usually,
values >1.5 are considered as evidence of intrathecal syn-
thesis of antibodies to the respective antigen [13, 14].
However, if titres instead of concentrations are used to
calculate the AI, a more conservative cut-off of 4 has been
recommended [10]. Reiber’s empiric hyperbolic function
Qlim was applied to control for possible underestimation
of intrathecal specific synthesis due to disturbances of the
blood-CSF barrier function [15]:
QlimðIgGÞ ¼ 0:93
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ðQAIbÞ2 þ 6 10−6
q
−1:7 10−3
In the case of QIgG > Qlim(IgG), AIITPR1 was calculated
as the ratio of QITPR1 and Qlim(IgG), i.e. AIITPR1 = QITPR1/
Qlim(IgG). For assessment of the AI, serum samples were
tested at dilutions of 1:10, 1:32, 1:100, 1:320, 1:1,000,
1:3,200 and 1:10,000. CSF samples were tested undiluted,
at 1:10 dilution and, in addition, at dilutions that would
indicate intrathecal production as defined by an ITPR1-AI
of >4. The CSF/serum albumin ratio, QAlb = AlbCSF[mg/l]/
Albserum[g/l], was used to assess the blood-CSF barrier
function. The upper reference limit of QAlb, Qlim(Alb), was
calculated as 4 + (a/15), with a representing the patient’s
age [15]. Total IgG and albumin values were determined
nephelometrically.
Peripheral blood mononuclear cell phenotype profiling
PBMCs were isolated from peripheral blood from patient
1 and a healthy control by density gradient centrifugation
using Ficoll-Hypaque (Biochrom AG, Berlin, Germany)
and immediately subjected to multi-colour flow cyto-
metric analysis. For B cell phenotyping, 106 PBMCs were
stained with fluorescent-dye-labelled monoclonal anti-
bodies (mAbs) specific for CD20, CD27 and IgD. Stained
cells were first gated for CD20+ (total B cells), followed by
CD27/IgD dot-plot analysis identifying CD20+CD27−IgD+
naïve, CD20+CD27+IgD+ non-switched memory B cells,
and CD20+CD27+IgD− isotype class-switched memory B
cells [16]. For detection of T lymphocytes, 106 PBMCs
were stained with fluorescent-dye-labelled mAbs specific
for CD3, CD4, CD8 and CD45RO. Stained cells were first
gated for CD3 (total T cells), followed by CD4/CD45RO
and CD8/CD45RO dot-plot analysis to identify CD3+CD4
+ T-helper cells, CD3+CD4+CD45+ memory T-helper cells,
CD3+CD4+CD45RO− naïve T-helper cells, CD3+CD8+
cytotoxic T cells, CD3+CD8+CD45+ memory cytotoxic T
cells and CD3+CD8+CD45RO− naïve cytotoxic T cells. All
mAbs were purchased from BD Pharmingen (Heidelberg,
Germany). Fluorescence-activated cell sorting (FACS) data
acquisition was performed with a FACS Calibur™ cyt-
ometer and analysed with CellQuest™ software (BD Biosci-
ences, Heidelberg, Germany).
Blood cell proliferation assay
Mononuclear blood cells (2 × 105/200 μl) from patient 1
(sample obtained prior to tumour therapy) and a healthy
control donor were cultured in triplicate in U-bottom
microtitre wells (TPP Techno Plastic Products AG,
Trasadingen, Switzerland) in RPMI 1640 medium sup-
plemented with 10 % heat-inactivated AB human serum
(Sigma Chemie), 2 mM L-glutamine and 100 U/ml
penicillin-streptomycin and incubated with either puri-
fied native rat ITPR1 (10 μg/ml) [17], purified human
glial fibrillary acidic protein (GFAP) (10 μg/ml) (Merck
Chemicals, Darmstadt, Germany) or phosphate buffered
saline (PBS) (Euroimmun). The proliferative response was
measured by the uptake of 3H-thymidine (0.5 μCi/well)
added 16 h before harvesting on day 3 of culture. The
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responses are reported as the mean counts per minute
(cpm) values of three cultures.
Peripheral blood lymphocyte phenotype profiling
Mononuclear blood cells (1.5 × 105) from the patient and
the healthy control were cultured in 200 μl culture
medium in triplicate together with either ITPR1 protein
(10 μg/ml) or GFAP protein (10 μg/ml). Twelve days
later, autologous mononuclear blood cells irradiated at
30 Gy were added at a final concentration of 5 × 104 cells
per well, as antigen-presenting cells, and the proliferative
response was boosted by addition of 10 μg/ml ITPR1 or
GFAP protein. The cells were harvested on day 15 of
culture. This protocol was used to expand the ITPR1-
responding cell lines. No cytokine was added. The
proportions of T and B cell subtypes in culture were
determined by FACS following the protocol used for
peripheral blood lymphocyte phenotype profiling de-
scribed above.
Results
Clinical and electrophysiological findings
Case 1. A 60-year-old male heavy smoker (35 pack-
years) with no significant neurological history developed
severe weakness of the lower legs, which rapidly
ascended within 1 week, involving first the thighs and
hip muscles, then the muscles of both arms, followed by
the respiratory muscles and the mimic muscles on day 6.
At first presentation at our department 7 days after on-
set, severe paresis of the hip flexors (Medical Research
Council [MRC] grade 2/5), moderate paresis of the knee
flexors (3/5), mild paresis of the feet flexors and exten-
sors (4/5), mild (and also mainly proximal) paresis of the
upper limbs (4/5), peripheral facial nerve paresis and
mild dysarthrophonia were present. Motor symptoms
were accompanied by paraesthesia and hypoaesthesia of
the legs, trunk (up to level Th10) and hands and by
pallanaesthesia of the upper and lower extremities. Deep
tendon reflexes of the lower and upper extremities were
absent; Babinski’s sign was negative. Of particular note,
most severe pain was present since onset, which
ascended from the lower legs to the thighs and to the
lumbar region and which required treatment with
tilidine, metamizole and gabapentin. Further complaints
included impaired micturition and irregular defaecation
(with diarrhoea) for several months. Within the last
month before onset, the patient had unintentionally lost
5 kg of body weight. MRI of the brain and spinal cord
(without gadolinium) showed no abnormalities. Lumbar
puncture demonstrated albuminocytologic dissociation
and systemic immune activation (Table 1). Nerve con-
duction studies first revealed severely delayed and miss-
ing F waves, indicating damage to the proximal motor
nerve axons or anterior horn α-motor neuron cell
bodies, A waves, and, later, delayed motor nerve conduc-
tion velocities and decreased sensory nerve action po-
tentials (Table 2). Moreover, a marked side difference in
motor neuron conduction velocity and distal motor la-
tency of the facial nerve was detected, confirming a right-
sided cranial nerve involvement. In addition, involvement
of the autonomic nervous system, as indicated by reduced
pathological heart rate variability, was noted. Guillain-
Barré syndrome (GBS) was suspected, though anti-
ganglioside antibodies (GM1-IgG, GM1-IgM, GQ1b-IgG,
GQ1b-IgM, GD1a-IgG, GD1a-IgG, GD1b-IgG, GD1b-
IgM) were negative. Serology and faecal culture for Cam-
pylobacter spp., Salmonella spp., Yersinia spp. and Shigella
spp. were negative. Serum levels of vitamin B12, B1 and
B6, folic acid and vitamin E were normal. To rule out a
paraneoplastic aetiology, the patient’s serum was tested for
anti-neural antibodies. IHC on brain tissue section re-
vealed high-titre IgG antibodies binding to PCs in a pat-
tern similar to that described for anti-Sj/ITRP1-IgG
antibodies [1], and the presence of anti-ITPR1-Ab was
subsequently confirmed in two methodologically inde-
pendent assays, a rat ITPR1-specific dot-blot assay and a
human ITRP1-specific CBA (see section “Serological find-
ings” below for details). Treatments with plasma exchange
(PEX) (7×) and, subsequently, intravenous immunoglobu-
lins (5 × 25 g) did not result in significant clinical improve-
ment. In line with the lack of treatment response, ITPR1-
IgG was still detectable at a titre of 1:1000 (CBA) 7 days
after PEX. Chest computed tomography (CT) showed a le-
sion compatible with lung cancer. Serum neuron-specific
enolase, CYFRA21-1 and squamous cell carcinoma
Table 1 Cerebrospinal fluid findings in patient 1
d6 d24
Total protein 1571 mg/day 225 mg/day
CSF cell count Normal Normal
QAlb 34 48
Blood-CSF barrier dysfunction Yesa Yesa
Albuminocytologic dissociation Yes Yes
CSF lactate Normal Normal
CSF glucose Normal Normal
OCBs Mirror patternb Mirror patternb
QIgG Normal Normal
QIgA Normal Normal
QIgM Normal Normal
MRZ reaction Negative N.d.
No antibodies to Borrelia burgdorferi, Treponema pallidum and Mycobacterium
tuberculosis were detected in CSF and serum. CSF-PCR for EBV, HSV-1, HSV-2
and VZV was negative as well
QAlb CSF/serum Alb ratio, QIgG CSF/serum IgG ratio, QIgA CSF/serum IgA ratio,
QIgM CSF/serum IgM ratio, MRZ reaction measles, rubella, zoster reaction [61–63],
N.d. not done
aAs indicated by an elevated CSF/serum albumin ratio
bIndicates systemic immune activation
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antigen levels were normal. A biopsy from the lesion re-
vealed an adenocarcinoma of the lung (TTF1-positive,
negative for markers of neuroendocrine differentiation
such as chromogranin A and synaptophysin 38). After
surgical removal of the tumour (UICC classification:
pT1b pN0 [0/18] L0 V0 Pn0 G2 R0), mild clinical
improvement was noted, though the patient was still
not able to walk or stand. CBA titres had declined to
1:320 by 1 month after operation. Around 1 year after
onset, he developed repeat brain infarction, which led
to Broca aphasia and brachiofacial hemiparesis on the
right side and was attributed to intermittent atrial fib-
rillation by the then treating physicians. At a follow-
up visit, another 4 months later, the paresis of the left
arm had completely resolved and only mild paresis of
the left leg remained. As sequelae of the two stroke
episodes, persisting central facial paresis, complete
paresis of the right arm, severe paresis (3/5) of the
right leg and motor aphasia were noted. The patient
had gained a significant amount of weight (from
48 kg before tumour removal to 60 kg at last follow-
up), and regular oncological follow-up examinations
had shown no signs of tumour recurrence. Serum
anti-Sj/ITPR1-IgG was still detectable, although at
lower titre (CBA 1:100).
Case 2. A 40-year-old man developed bilateral paraes-
thesia of the lower limbs ascending to the thighs with no
manifest paresis. SSEP revealed delayed latency from the
lower extremities. Clinical examination revealed hypore-
flexia of the lower limbs. The patient's serum IgG
bound to murine brain tissue sections in a pattern
suggestive of ITPR1-IgG, the presence of which was
confirmed by CBA and immunoblot. Bence Jones pro-
teinuria indicated multiple myeloma. In a follow-up
sample taken 5 months later, the antibody was still
detectable. While the patient’s peripheral symptoms
had progressed only slowly, severe depression of un-
known cause had occurred in the meantime. Antinu-
clear and anti-dsDNA antibodies as well as anti-
ganglioside antibodies were negative.
Case 3. A 79-year-old man developed slowly progressive
distal weakness of the upper extremities and disturbance
of fine motor skills in the right hand. Some months later,
he noted increasing weakness also of the left hand. Upon
neurological examination, flaccid paresis (MRC grades
2–4 at first examination, 0–4 at 32 months) and atrophy
of the small muscles of both hands, mild paresis of the toe
extensors, hypo- and areflexia in the upper and lower ex-
tremities, hypoaesthesia of both feet and pallhypoaesthesia
in the upper and lower extremities (radius 4/8, patella 2/8,
Table 2 Electroneuronography and heart rate variability (HRV) findings in patient 1 at days 7 (d7), 24 (d24), 31 (d31), 40 (d40) and 62
(d62), demonstrating axonal and demyelinating sensorimotor poly(radiculo)neuropathy with lost and delayed F waves and
autonomic involvement, compatible with Guillain-Barré syndrome
CMAP [mV] DML [ms] mNCV [m/s] F waves [ms] A waves SNAP [μV] sNCV [m/s]
Tibial nerve, right Sural nerve, right
d7 10.9 (n) 3.8 (n) 41 (n) 64.3 (↑) Yes 9.1 (n) 52.6 (n)
d24 6.8 (n) 5.2 (n) 36.7 (↓) Lost Yes 6.4 (n) 50 (n)
d40 2.5 (↓) 5.5 (n) 25 (↓) Lost N.d. 5.8 (n) 47.5 (n)
d62 0.6 (↓) 8.5 (↑) 33 (↓) Lost N.d. N.d. N.d.
Ulnar nerve, right Ulnar nerve, right
d7 10.6 (n) 2.5 (n) 60 (n) 29.9 (n) N.d. 2.3 (↓) 45.8 (n)
d24 8.6 (n) 2.8 (n) 38.5 (↓) 34.6 (↑) N.d. N.d. N.d.
d40 9.5 (n) 3.8 (↑) 47 (n) 42.1 (↑) N.d. Lost Lost
Facial nerve, righta
d31 0.4 (↓b) 5.2 (↑b)
Facial nerve, leftc
d31 0.9 4.3
HRV [%]
d7 17 (n)
d24 8.7 (↓)
Note the continuous deterioration of almost all sensory and motor modalities over the course of the disease. Pathological results are printed in italicized letters
N.d. no data, CMAP compound muscle action potential, DML distal motor latency, mNCV motor nerve conduction velocity, SNAP sensory nerve action potential,
sNCV sensory nerve conduction velocity; ↑ increased, ↓ decreased
aSymptomatic
bCompared with left facial nerve
cAsymptomatic
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malleus 2/8) were noted. Ganglioside antibodies were re-
peatedly negative. Electroneuronography demonstrated
delayed and lost F waves, A waves, decreased and lost
compound muscle action potentials, missing sensory
nerve action potential or reduced sensory nerve conduc-
tion velocities in the upper and lower extremities and no
conduction blocks (Table 3). Electromyography revealed
spontaneous activity indicating denervation (fibrillations
and positive sharp waves) in five muscles on three levels
and fasciculation in six muscles on three levels. The CSF
findings (including OCBs) were unremarkable, as was
MRI of the cervical spinal cord. Serum ITPR1-IgG was
tested for the first time 23 months after onset and was
positive at a titre of 1:100 (CBA); both of two follow-up
samples were positive as well. No other anti-neural anti-
bodies were detected.
Neuropathological findings
A biopsy sample of the right sural nerve was available
from patient 1. The sample was obtained 70 days
after onset. Histopathology demonstrated neuritis with
several small perivascular cell infiltrates consisting of
CD8-positive lymphocytes directly adjacent to small
epineural vessels, partly arranged in a bead-like man-
ner and partly invading the adventitia. Analysis of the
neurofascicles showed oedema (most pronounced in
the subperineural area), a markedly broadened peri-
neurium, severe irregular loss of myelinated axons
(with myelin-positive, CD68-positive macrophages
present, indicating florid inflammation) and marked
endoneural fibrosis. Staining with antibodies to IgG,
IgA and IgM revealed severe blood-nerve barrier
disruption.
Table 3 Electroneuronography findings in patient 3 at 6 months (m6), 9 months (m9) and 32 months (m32) after onset, demonstrating
axonal and demyelinating sensorimotor poly(radiculo)neuropathy with, as in patient 1, lost and delayed F waves of the upper and
lower extremities
CMAP [mV] DML [ms] mNCV [m/s] F waves [ms] A waves SNAP [μV] sNCV [m/s]
Tibial nerve, right Sural nerve, right
m6 1 (↓) 7.24 (↑) Normal 67.4 (↑) N.d. N.d. N.d.
m9 1.6 (↓) Normal Normal 56.8 (↑) N.d. N.d. N.d.
m32 1.4 (↓) Normal Normal Lost N.d. N.d. N.d.
Tibial nerve, left Sural nerve, left
m6 N.d. N.d. N.d. N.d. N.d. Missing Missing
m9 3.1 (↓) Normal Normal 63.8 (↑) N.d. N.d. N.d.
m32 2.6 (↓) Normal Normal 66 (↑) N.d. Missing Missing
Median nerve, right Median nerve, right
m6 1.4 (↓) 5.09 (↑) Normal Lost Yes 7.6 (↓) Normal
m32 N.d. N.d. N.d. N.d. N.d. Normal Normal
Median nerve, left Median nerve, left
m6 2.7 (↓) 4.42 (↑) Normal Lost Yes Normal Normal
Ulnar nerve, right Ulnar nerve, right + left
m6 N.d. N.d. N.d. N.d. N.d. N.d. N.d.
m9 Normal Normal Normal Normal N.d. N.d. N.d.
m32 Normal Normal Normal 33.2 (↑) N.d. N.d. N.d.
Ulnar nerve, left Ulnar nerve, left
m6 Normal Normal Normal Normal N.d. Normal Normal
m9 N.d. N.d. N.d. N.d. N.d. N.d. N.d.
m32 N.d. N.d. N.d. N.d. N.d. Normal 40 (↓)
Peroneal nerve (m. extensor digitorum brevis), left
m6 Lost Lost Lost Lost
m9 N.d. N.d. N.d. N.d.
m32 Lost Lost Lost Lost
Pathological results are printed in italicized letters
N.d. no data, CMAP compound muscle action potential, DML distal motor latency, mNCV motor nerve conduction velocity, SNAP sensory nerve action potential,
sNCV sensory nerve conduction velocity; ↑ increased; ↓ decreased
Jarius et al. Journal of Neuroinflammation  (2016) 13:278 Page 6 of 17
Serological findings
Patients 1 and 2 were both positive for ITPR1-IgG as de-
tected by IHC, CBA and immunoblotting. All samples
showed the typical staining pattern on cerebellum tissue
sections previously described with ITPR1-IgG-positive
sera, i.e. staining of the PC somata, dendrites and axons,
sparing the PC nucleus as well as all other cells of the
cerebellum, at high titres (patient 1: 1:15,000; patient 2:
1:2,500) [1]. Simultaneous incubation of tissue sections
with patient IgG and a commercial antibody to ITPR1
resulted in identical staining patterns (Fig. 1); by con-
trast, no double labelling was seen with healthy control
samples. Moreover, both sera reacted with ITPR1-
transfected HEK293 cells but not with mock-transfected
HEK293 cells used as control substrate in the CBA (pa-
tient 1: >1:1,000; patient 2: 1:1,000). Finally, the samples
reacted with purified rat ITPR1 in the dot-blot assay
(Fig. 1). Patient 3 was not tested at disease onset but
only at 23 months, when he was positive for serum
ITPR1-IgG as detected by CBA at a titre of 1:100. He
remained positive when re-tested 1 month (1:32) and
4 months later (1:10); IHC showed faint staining of PCs
at serum dilutions of 1:10 and 1:60.
A broad panel of other anti-neural antibodies (anti-Ca/
ARHGAP26, anti-Homer-3, anti-CARPVIII, anti-Hu, anti-
Ri, anti-Yo, anti-Tr/DNER, anti-Ma/Ta, anti-GAD65, anti-
Fig. 1 ITPR1-IgG as detected by a immunohistochemistry, b a dot-blot assay and c, d a cell-based assay (exemplary findings). a Binding of patient
serum IgG and of a commercial antibody to ITPR1 to formalin-fixed mouse (as well as rat and primate, not shown) cerebellum tissue sections
(MoL molecular layer, PCL purkinje cell layer). Binding of patient IgG is depicted in green (goat anti-human IgG Alexa Fluor® 488); binding of a
commercial rabbit anti-ITPR1 antibody in red (goat anti-rabbit IgG Alexa Fluor® 568); yellow indicates binding of both antibodies. Cell nuclei were
stained by 4',6-diamidino-2-phenylindole (blue colour). b Binding of IgG from the patient’s serum and from two previously reported ITPR1-IgG-positive
patients [1] to purified native ITPR1 from rat brain in a dot-blot assay; by contrast, sera from four healthy and disease controls did not bind to ITPR1. A
commercial goat anti-human IgG antibody labelled with IRdye®700 (Rockland, Limerick, PA) was used to detect bound patient IgG. c Binding of patient
IgG to cells transfected with mouse ITPR1 (left) but not to mock-transfected HEK293 cells used as control substrate (right). Binding of patient IgG was
visualized using a goat anti-human IgG secondary antibody labelled with fluorescein isothiocyanate. See the “Methods” section for details.
ACA autoimmune cerebellar ataxia, PEX plasma exchange
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amphiphysin, anti-CV2/CRMP5, anti-recoverin, anti-
SOX1, anti-titin, anti-Zic4, anti-AQP4, anti-MOG,
anti-NMDAR, anti-GAGAB receptors, anti-LGI1, anti-
CASPR2, anti-glycine receptors, anti-ganglioside anti-
bodies) was negative.
A CSF sample (taken 25 days after onset) was avail-
able from patient 1 and was positive for ITPR1 at a
titre of 1:32 in the CBA. This corresponded to an
ITPR1-IgG AI of 1.65 according to Reiber’s formula
(see “Methods” section for details), based on an
ITPR1-IgG CBA titre of 1:1000 at the time of lumbar
puncture, an IgG CSF/serum ratio of 19.4 and an al-
bumin CSF/serum ratio of 48. When tested at 1:78
dilution, which would correspond to an AIITPR1 of 4,
indicating intrathecal synthesis, no ITPR1-IgG anti-
bodies were detectable, suggesting a predominantly
extrathecal origin of CSF anti-Sj/ITPR1-IgG in line
with the finding of identical (i.e., no CSF-restricted)
OCBs in CSF and serum and a normal QIgG in this
case. ITPR1-IgG was also detectable in the CSF by
IHC on cerebellum tissue sections at a titre of 1:256
(Fig. 2). However, based on a serum titre of 1:15,000,
a CSF titre of 1:1182 would have been required to
achieve an AIITPR1 of 4, again suggesting an extrathe-
cal synthesis of anti-Sj/ITPR1-IgG in this case. No
CSF samples were available for testing from patients
2 and 3.
As in the previously reported index case [1], serum
ITPR1-IgG belonged exclusively to the IgG1 subclass in
the severely affected patient 1 (Fig. 3a). In addition,
ITPR1-IgA was present (Fig. 3b, inset) but no ITPR1-IgM.
By contrast, serum ITRP1-IgG in the more mildly affected
patients 2 and 3 was of the IgG2 subclass (Fig. 3b).
Immunological findings
Demonstration of ITPR1-specific PBMCs by use of a
3H-thymidine proliferation assay
After 3 days’ incubation, almost 70 % stronger 3H-thymidine
uptake was measured in the patient PBMC cultures stimu-
lated with ITPR1 (mean of three cultures 1980 counts per
minute (cpm)) than in those stimulated with GFAP (mean
1179 cpm) (Fig. 4a). By contrast, no such strong difference
in 3H-thymidine uptake was found between ITPR1- (mean
1131 cpm) and GFAP-stimulated (mean 949 cpm) healthy
donor control PBMCs. The patient’s ITPR1 response
exceeded that of the control patient by 75 % (Fig. 4a). If
the control GFAP response was subtracted from the
ITPR1 response (Δcpm), the response of the patient’s
PBMCs to ITPR1 exceeded that of the healthy control
donor PBMCs by 337 % (Δcpmpatient 800 cpm vs ΔcpmHC
183 cpm) (Fig. 4b). Stimulation with PBS used as negative
control resulted in similar 3H-thymidine uptake by patient
and healthy donor PBMCs (mean of three cultures 280
and 277 cpm, respectively).
Demonstration of ITPR1-specific B cells and CD3+CD4+ T
cells among patient PBMCs
The proportion of B cells among total patient PBMCs
was higher after ITPR1 stimulation (15.3 %) than after
GFAP stimulation (10.5 %). This corresponded to an ab-
solute difference of 45 %. By contrast, ITPR1 was even a
slightly weaker stimulus than GFAP when used to stimu-
late healthy control PBMCs (Fig. 5). The proportion of
CD3+CD4+ cells among total patient PBMCs was also
higher after ITPR1 stimulation (56 %) than after GFAP
stimulation (43.1 %). This corresponded to an absolute
difference of 30 %. By contrast, the difference was only
Fig. 2 ITPR1-IgG in the CSF. Perfect overlap of the patient IgG from a CSF sample (patient 1) with a commercial antibody to ITPR1 as detected by
IHC on a murine cerebellum tissue section. Bound patient IgG is depicted in green (Alexa Fluor® 488) and binding of the commercial anti-ITPR1
antibody in red (Alexa Fluor® 568); yellow indicates areas stained by both antibodies. Cell nuclei were stained by 4',6-diamidino-2-phenylindole (blue)
Jarius et al. Journal of Neuroinflammation  (2016) 13:278 Page 8 of 17
Fig. 3 ITPR1 class and subclass analysis revealed IgG1 a and IgA (b, inset) antibodies in patient 1 and IgG2 antibodies in patient 2 (as well as in
patient 3, not shown) b
Fig. 4 3H-thymidine uptake (cpm; mean of three stimulations) in proliferating PBMCs from patient 1 and from a healthy control following
stimulation with ITPR1 or GFAP, respectively. a Note the significantly higher 3H-thymidine uptake in patient PBMCs stimulated with ITPR1 than in
the healthy donor; by contrast, no difference was noted after stimulation with GFAP or with PBS. b After subtraction of non-antigen-specific,
GFAP-induced proliferation, a difference (Δcpm) between patient and healthy control of more than 600 cpm or 340 % was noted following
ITPR1 stimulation
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1.9 % when healthy control samples were used (Fig. 5).
While no such difference between ITPR1 and GFAP
stimulation was found for total CD8 cells (neither
among patient nor among healthy control PBMCs) (not
shown), an around 10 % higher proportion of memory
cells (CD3+CD8+CD45RO+ phenotype) among total
CD8 T cells was found after 15-day stimulation with
ITPR1 than after stimulation for the same period of time
with GFAP (Fig. 5). No relevant differences were found
for the other markers investigated (see Methods section
for details).
Demonstration of ITPR1 expression in the spinal cord and
peripheral nervous system
ITPR1 has been previously shown to be expressed also in
the posterior and anterior horn of the spinal cord [2, 3]
and in the sensory neuron somata in the DRG (Fig. 6). We
were able to reproduce those previous findings using a
commercial antibody to ITPR1 (Fig. 6g, j). In addition, we
demonstrated expression of ITPR1 by the sural nerve
(Fig. 6h). To exclude non-specific binding or cross-
reactivity of the commercial antibody used, we employed
a second commercial antibody to ITPR1 (Alomone Labs,
Jerusalem, Israel) resulting in an identical binding pattern
(not shown). As a proof of principle, we incubated serum
samples from patient 1 and from two further ITPR1-IgG-
positive patients with rat DRG tissue sections and found
strong binding to the sensory DRG neurons in a pattern
identical to that seen with the commercial ITPR1 antibody
(Fig. 6i, j).
Demonstration of ITPR1 expression by the patient’s
adenocarcinoma
ITPR1 has been shown to be expressed in a subset of
adenocarcinomas of the lung as demonstrated by Western
blot and conventional immunohistochemistry; by contrast,
no or only low levels of ITPR1 protein expression have
been reported in normal lung tissue [18, 19]. Incubation
of the only cryosections of the adenocarcinoma of patient
1 available for research with a commercial antibody to
ITPR1 revealed ITPR1 expression by a subset of cells
which was identical to that obtained by incubating the
sections with an ITPR1-IgG-positive CSF sample from the
same patient (Fig. 7).
Discussion
Autoantibodies to ITPR1 (also termed anti-Sj after the
index sample) were originally described by some of us in
patients with ACA [1, 20–22]. The results from the
present study suggest that the spectrum of symptoms as-
sociated with autoimmunity to ITPR1 may be broader
than initially thought and may include motor, sensory (in-
cluding severe pain) and autonomic symptoms compatible
with (myelo)radiculopathy and/or peripheral neuropathy.
Clinical and aetiopathogenetic considerations
The latter hypothesis would be well in line with the fact
that ITPR1 is not exclusively expressed in the brain but
is present also in the anterior and posterior (including
the substantia gelatinosa) horns of the spinal cord [2, 3],
in the sensory DRG, in the trigeminal ganglia, in the
sympathetic ganglia [2], and in the peripheral nerves.
Fig. 5 Increase in the proportion of B cells, CD4+ T cells and CD8+CD45RO+ T cells among PBMCs from patient 1 (2 × 105 cells) following stimulation
with ITPR1 (10 μg/ml) (orange outlines) compared with stimulation with GFAP (10 μg/ml) and compared with healthy donor PBMCs stimulated with
the same amount of ITPR1 or GFAP, respectively
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Fig. 6 Expression of ITPR1 in the spinal cord (a, e–g), sural nerve (h) and dorsal root ganglia (DRG) (b–d, i–j) of adult mouse (a, d), rat (b–c, e–f, i–j)
and rhesus monkey (g–h) and as detected by in situ hybridization (a, b, e) and immunostaining (c–d, f–j), and binding of IgG from the patient’s CSF
(i) and serum (j) to sensory neuron somata in rat DRG as detected by indirect immunofluorescence. A polyclonal rabbit antibody to ITPR1 (Dianova)
and an AlexaFluor®568-labelled goat anti-rabbit IgG secondary antibody were used to detect ITPR1 expression (red). A fluorescein isothiocyanate-
labelled goat anti-human IgG antibody was used to visualize bound patient IgG (green). Yellow areas in j indicate overlay of the patient’s IgG and the
commercial ITPR1 antibody. a Taken from the Allen Spinal Cord Atlas [64] (http://mousespinal.brain-map.org/). b, c and e Reproduced from Dent et al.
[2] with kind permission of the publisher , d from Zhuang et al. [5] (made available under the Creative Commons CC0 public domain dedication;
https://creativecommons.org/publicdomain/zero/1.0/) , and f from Sharp et al. [3] with kind permission of the publisher. DH dorsal horn, IP3R
inositol-1,4,5 trisphosphate receptor
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Accordingly, signs and symptoms of peripheral nervous
system (PNS) involvement (reduced sensory conduction
velocity of sural nerve and motor conduction velocities
of the median and tibial nerves; reduced muscle stretch
reflexes and vibration sense) have been described in a
subset of patients with mutations in the ITRP1 gene [23,
24], and dysregulation of ITPR1 has been found to cause
allodynia and hyperalgesia in an animal model [5].
The presence of lung cancer suggests a paraneoplastic
aetiology in patient 1. Lung cancer is the most common
type of tumour in patients with paraneoplastic neurological
disorders (PND). However, no antibodies typically found in
patients with lung cancer and PND [25], including anti-Hu,
anti-CV2/CMRP5, anti-amphiphysin, anti-VGCC, anti-
SOX1, anti-GABABR and anti-AMPAR, were present in
our patients. ITPR1 has been shown to be expressed in a
broad variety of tumours (partly ectopically), particularly in
Hodgkin disease (HD) and malignant lymphoid and mye-
loid cell lines, but also lung cancer, melanoma, prostate
cancer and many other tumour entities [18]. In patient 2,
Bence Jones proteinuria in fact indicated the presence of a
non-Hodgkin (B cell) lymphoma and thus a possible para-
neoplastic aetiology in this patient as well. By contrast, no
evidence of cancer was present in patient 3 at last follow-
up.
Patient 1 presented with ascending motor and sensory
symptoms suggestive of GBS. Subacute sensory neuro-
nopathy (Denny-Brown syndrome) and subacute motor
neuropathy both represent “classical paraneoplastic
syndromes” according to an international consensus
definition [25]; GBS, acute sensorimotor neuropathy and
autonomic neuropathy, on the other hand, are well-
recognized “non-classical”, non-obligatory paraneoplastic
syndromes [25]. While GBS is considered to be of non-
paraneoplastic origin in the vast majority of cases,
numerous reports of GBS in oncological patients exist,
and a population-based study found an increased
frequency for tumours in patients with GBS (odds
ratio ~2.4) [26]. Associated tumours reported in GBS were
mainly lung cancer, Hodgkin lymphoma, non-Hodgkin
lymphomas and leukaemia, though several other types of
cancer were occasionally described (see Additional file 1:
Table S1 for a comprehensive list and references).
A paraneoplastic aetiology of ITPR1-IgG-associated
autoimmunity in patient 1 is further suggested by the
finding of ITRP1 expression in the tumour tissue in
structures also stained by the patient’s IgG. According to
proteomic data, ITPR1 is not constitutively expressed in
normal lung tissue or only at low level [18]. Of note,
ITPR1 has been detected at protein level only in a subset
of adenocarcinomas of the lung [18, 19], leaving the pos-
sibility that anti-ITPR1 seropositivity in patients may de-
note a subtype of adenocarcinoma in patients with lung
cancer and PND.
Fig. 7 ITPR1 is expressed in a subset of carcinomas of the lung.
a Quantitative Western blot analysis showing ITPR1 expression as
percentage of the ITPR1 expression in normal human bronchial epithelial
(NHBE) cells, in the small cell lung cancer cell line H1339 and in the non-
small cell lung cancer cell line HCC. The expression of IP3R was increased
with H1339 showing the highest expression (n=4, *P< 0.01 versus all
other groups). Image reproduced from Bergner et al. (2009) [19]
(distributed under the terms of the Creative Commons Attribution
License [http://creativecommons.org/licenses/by/2.0]). b–d Indirect
immunofluorescence-based immunohistochemistry assay showing
ITPR1 expression within adenocarcinoma tissue obtained from patient
1 (b binding of a commercial rabbit antibody to ITPR1 visualized using
a goat anti-rabbit IgG Alexa Fluor® 568-labelled secondary antibody
[red fluorescence]; c binding of patient serum IgG visualized by use of a
goat anti-human IgG secondary antibody labelled with Alexa Fluor® 488
[green fluorescence]; d staining of cell nuclei by DAPI [blue fluorescence])
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Whether anti-ITPR1 autoimmunity has a protective role
in patients with PND, as suggested for other antibody-
related syndromes such as anti-Hu, is currently unknown
but warrants further investigation. Of potential interest in
this context, ITPR1 has been reported to protect renal
cancer cells from NK-mediated lysis [27]. In vivo, ITPR1
targeting significantly enhanced NK-mediated tumour re-
gression [27].
Some paraneoplastic disorders, including anti-Hu,
anti-CV2/CRMP5 and anti-amphiphysin syndrome, have
been shown to be capable of causing both central and
peripheral neurological symptoms, in line with the pres-
ence of the respective autoantigens in both central and
peripheral nervous tissue. Similarly, ITPR1 is expressed
both in the CNS and in the PNS. Why one and the same
paraneoplastic neurological disorder affects the CNS in
some patients but the PNS in others (and both systems in
yet others) is not well understood. However, differences in
blood-brain/CSF barrier function among patients or varia-
tions hereof over time in the same patient, the presence or
absence of antigen-specific intrathecal B and T cell clones,
differences in antigen/epitope availability among tissues
and, importantly, differences in antibody epitope/isoform
specificity could play a role. To date, eight isoforms of
ITPR1 produced by alternative splicing have been de-
scribed [28]. Future studies need to address (a) possible
cross-reactivity of anti-ITPR1-IgG with ITPR2 and ITPR3
as well as among the various ITPR1 isoforms and (b) dif-
ferences in epitope/isoform specificity between patients
with ITPR1-IgG-associated ACA and ITPR1-IgG-positive
patients with peripheral nervous system involvement.
In the adult brain, ITPR1 is not only expressed in PCs
of the cerebellum but also in hippocampal neurons (par-
ticularly in CA1 pyramidal cells) [2–4], in the putamen
and the caudate nucleus, and in the cerebral cortex
(most pronounced in pyramidal layer V and non-
pyramidal layer II) [2, 3]. Given this wide expression
profile, it is likely that the spectrum of ITPR1 autoimmun-
ity will broaden further as more patients are identified in
the future. In this context, it is worth noting that patient 2
developed severe depression in the course of disease. Signs
of possible limbic involvement (confusion, severe memory
loss, suspected temporal lobe epilepsy) were also present
in two recent ITPR1-IgG-positive patients identified by
the authors, one of whom also had cerebellar ataxia
(unpublished data).
In the light of ITPR1 being expressed in the auto-
nomic nervous system, in particular in the sympathetic
ganglia [2], it is of special note that patient 1 exhibited
reduced pathological heart frequency variability, a typical
sign of autonomic neuropathy of the heart, and later de-
veloped repeated stroke episodes attributed to intermit-
tent atrial fibrillation. Interestingly, ITPR1 is also present
in human and murine cardiac myocytes [18, 29, 30],
where it is involved in crucial regulation of intracellular
calcium pathways: The cardiac ITPR receptors have re-
cently been shown to modulate the electromechanical
properties of the human myocardium and its propensity
to develop arrhythmias [29]. Further studies on anti-
ITPR1 autoimmunity should therefore pay attention also
to signs and symptoms of autonomic heart dysregulation
and autoimmune myocarditis.
It is of further interest in this context that patient 1 re-
ported continuous bowel dysfunction with diarrhoea
starting several months before onset of the polyradiculo-
neuropathy. Whether these symptoms were caused by
infection and whether an infectious agent was involved
in the pathogenesis of the patient’s neurological disorder
(e.g. molecular mimicry) remains unknown. No evidence
was found for an infection with Campylobacter jejuni,
which is present in around 30 % of patients with clas-
sical GBS. Alternatively, the patient’s bowel dysfunction
could have been a first sign of autonomic neuropathy.
The latter hypothesis is supported by the fact that he
simultaneously developed bladder dysfunction. ITPR1 is
expressed in the sympathetic ganglia as well as in the
smooth muscle cells of the bowel and the bladder. Ac-
cordingly, we found binding of IgG from this and other
ITPR1-IgG-positive patients to smooth muscle cells in
the enteric wall in a pattern identical to that seen with a
commercial antibody to ITPR1 [1]. Moreover, paraneo-
plastic enteropathy is a well-known complication of can-
cer, and diarrhoea has recently been recognized as a
typical prodromal symptom in DPPX (dipeptidyl-amino-
peptidase-like protein 6) syndrome, another novel
antibody-related autoimmune disease of the CNS [31–
34]. Studies evaluating the frequency of ITPR1-Ab in pa-
tients with paraneoplastic and other types of suspected
autonomic enteropathy seem therefore warranted.
Finally, the facts that ITPR1 is expressed in the sen-
sory DRG, the trigeminal ganglia and the substantia gel-
atinosa [3], in which C fibre axons synapse with neurons
of the pain-transmitting lateral spinothalamic tract and
damage to which can cause pain and hyperalgesia, and
that ITPR1 dysregulation has been implicated in hyper-
algesia and allodynia in animal studies [5], along with
the presence of a severe pain syndrome in our patient,
provide a preliminary rationale for seeking a potential
role of ITPR1-related autoimmunity also in patients with
pain syndromes of unknown aetiology.
Immunological considerations
Passive transfer experiments using IgG from anti-ITPR1-
positive patients have not yet been performed. Therefore,
no direct evidence for a pathogenic impact of the antibody
is currently available. ITPR1 is thought to be primarily an
intracellular antigen located in membranes encompassing
the endoplasmatic and, in muscle cells, sarcoplasmatic
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reticulum. Many researchers believe that intracellular anti-
gens are not accessible to antibodies in vivo. In fact, most
neurological autoantibodies of proven pathogenic im-
pact, such as antibodies to AQP4 in neuromyelitis
optica [35–38], acetylcholine receptor in myasthenia
gravis, VGCC in Lambert-Eaton syndrome [39] and
mGluR1 in paraneoplastic cerebellar degeneration
[40], target cell-surface-expressed proteins. Moreover,
passive transfer of antibodies to intracellular antigens
such as anti-Yo [41–43] has not produced clinical dis-
ease in animal studies. Instead, T cell-mediated im-
mune mechanisms directed against the target antigen
of the accompanying antibody have been proposed to
play a role in those disorders [44–47]. It is therefore
possible that the antibody has diagnostic but no
pathogenic impact, similar to the situation in many
paraneoplastic neurological disorders.
However, surface localization of ITPR1 has been reported
to occur under certain circumstances [48–52], warranting
further investigation. Moreover, studies demonstrating cell
damage following uptake of paraneoplastic antibodies by
neurons have somewhat challenged the above-mentioned
paradigm (see [20–22] for a summary). Indirect evidence
suggesting a potential pathogenic role of anti-ITPR1 in-
cludes the fact that the antibodies mainly belonged to the
complement-activating IgG1 subclass, the very high serum
titres in two of our patients (titres were lower in patient 2,
in whom ITPR1 was tested late in the disease course), the
decline in titres after tumour removal, which was accom-
panied by clinical stabilization and improvement, and the
good concordance of the antigen’s tissue expression profile
with the clinical symptoms present in our patient, in par-
ticular in patient 1. The absence of intrathecal ITPR1-IgG
synthesis does not per se argue against a pathogenic role of
the antibody: First, the antibody can still reach the CSF via
passive diffusion and/or a leaky blood-brain/CSF barrier
(ITPR1 was in fact present in the CSF and QAlb markedly
elevated in patient 1). Second, the blood-CSF barrier is
thought to be particularly leaky around the nerve roots.
Third, there is no need for intrathecal synthesis when it
comes to peripheral nerve damage. Finally, AIs are regularly
negative also in AQP4-IgG-positive neuromyelitis optica
spectrum disorders (NMOSD) [53] and in MOG-IgG-
positive encephalomyelitis [54–58], two diseases in which a
direct pathogenic impact of the antibody has been proven
or is highly likely.
Of note, anti-Sj/ITPR1-IgG was of the strongly
complement-activating IgG1 subclass in the severely af-
fected patient 1 (as well as in the severely disabled anti-
Sj/ITPR1-IgG index patient [1]), but exclusively of the
very weakly complement-activating IgG2 subclass in pa-
tient 2, who had relatively mild disease with no major
progression of his polyneuropathy after 1.5 years. Future
studies investigating the clinical associations of ITPR1-
related autoimmunity should therefore include IgG sub-
class analyses.
To investigate the role of cell-mediated immunity in
this disease, we studied the proliferative response of the
PBMCs from patient 1 and from a control donor to
stimulation with purified ITPR1 (boosted with radiated
antigen-presenting cells) and a control protein in vitro,
and assessed the PBMC surface phenotypes before and
after stimulation. Phenotypic analysis of the PBMCs re-
vealed a marked difference in proportions of B cells,
CD4 T cells and CD8 memory T cells between patient
and control donor after exposure to ITPR1. Moreover,
compared with the healthy donor the patient’s PBMCs
proliferated strongly as measured by 3H-thymidine
uptake after ITPR1 stimulation. Taken together, these
findings indicate that the patient’s PBMCs contained
ITPR1-specific B cells and autoreactive CD4 and CD8 T
cells, which could be directly involved in injury of the
nervous system as well as in antitumour immunity.
Serological and therapeutic considerations
Anti-Sj/ITPR1-IgG titres were extraordinarily high both
in the IHC assay (up to 1:15,000) and in the CBA (up to
>1:1000) during acute disease in patient 1; after removal
of the tumour (and thus of the ectopically presented
antigen), CBA titres declined to 1:320 and later 1:100.
Similarly, relatively high titres of anti-Sj/ITPR1-IgG were
noted in patient 2 (IHC 1:5,000) and in all of the previ-
ously reported ITPR1-IgG-positive cases (IHC 1:5,000,
1:3,200, 1:3,200, 1:1,000) [1]. In direct comparison, IHC
titres were higher on average than those in the majority
of patients with AQP4-IgG-positive NMOSD or MOG-
IgG-positive encephalomyelitis tested by the authors in
recent years using the same methodology [59, 60].
Patients 1 and 2 yielded a positive result in all three
assays employed, largely ruling out false-positive results
due to insufficient assay specificity. While mouse ITPR1
was used in the CBA, purified rat was employed in the
dot-blot assay, and primate, rat and mouse ITPR1 was
the antigenic substrate in the IHC assay. Similarly, all
previously reported patients reacted with all three anti-
gens. This suggests that the epitope targeted by ITPR1-
IgG in these patients was located in a region not rele-
vantly affected by differences in amino acid sequence
and/or confirmation between those species. Patient 3
was positive in the CBA and IHC assay but negative in
the dot-blot assay; while the reason remains unknown, it
is likely that this was due to sensitivity issues related to
the dot-blot assay, given that the sample repeatedly
yielded low titres in the CBA and in the IHC assay.
Interestingly, serum anti-Sj/ITPR1-IgG was still de-
tected at a titre of >1:1000 both in the IHC assay and in
the CBA after seven PEX treatments in patient 1, and
CSF ITRP1 was positive 18 days after the first PEX
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treatment in that patient. This is in line with the authors’
experience from other autoantibody-related neurological
syndromes, in which the pathogenic antibodies occa-
sionally persist after five to seven PEX treatments, indi-
cating that the number of PEX treatments usually
administered in neurological indications may be too low
to achieve complete autoantibody removal in some cases
and may need to be adjusted according to serological
findings. As a caveat, however, it should be kept in mind
that evidence for a direct pathogenic role of the antibody
is lacking so far and that the immune response in pa-
tients with paraneoplastic neurological syndromes may
contribute to controlling tumour growth and spread.
Moreover, T cells may be involved in the pathogenesis,
which would make it necessary to employ treatment mo-
dalities targeting not only the B cell and antibody arm of
the immune reaction but also the T cell arm.
Conclusions
In conclusion, our study expands the spectrum of clin-
ical manifestations associated with anti-Sj/ITPR1-IgG
and suggests that autoimmunity to ITPR1 may possibly
be involved in the pathogenesis of peripheral neuropathy
in selected patients, including in cases clinically suggest-
ive of GBS. Moreover, the presence of malignant tu-
mours in two of our patients as well as the expression of
ITPR1 within the tumour in one of them suggests a
paraneoplastic aetiology of ITPR1 at least in a subset of
patients. Studies on the frequency and syndrome specifi-
city of anti-Sj/ITPR1-IgG in patients with PNS disorders,
including, among others, GBS, autonomic neuropathies
and pain syndromes of unknown aetiology, are now war-
ranted. Lung cancer, haematological tumours and a
paraneoplastic origin should be considered in anti-Sj/
ITPR1-IgG-positive patients.
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